Clinical Insights Into Treatment Approach for Metastatic HER+  mBC Patient Case

Clinical Brief: Emerging Options for HER2+ mBC

Key Themes:

• Efficacy of Second-Line T-DXd: Trastuzumab deruxtecan (T-DXd) is becoming standard in the second-line setting, supported by National Comprehensive Cancer Network guidelines
• PATINA Trial Results: Adding palbociclib to trastuzumab/pertuzumab/AI maintenance therapy significantly improved progression-free survival (PFS) (44 vs 29 months) in hormone receptor (HR)+/HER2+ disease
• Biological Heterogeneity: Recognition that HR+, HER2+ disease differs biologically from HR-negative (HR–) disease

Key Points for Physicians:

• T-DXd is emerging as the preferred second-line therapy for HER2+ mBC
• The PATINA trial data demonstrate significant PFS benefit with the addition of CDK4/6 inhibition to maintenance therapy in HR+/HER2+ disease
• Insurance coverage for palbociclib in this setting remains challenging until formal guideline inclusion

Notable Insights:

• Approximately 50% of triple-positive (ER+/PR+/HER2+) tumors display luminal characteristics, which may influence treatment response
• The 15-month improvement in PFS with palbociclib addition in the PATINA trial was described as “shocking in the most wonderful way”
• DESTINY-Breast03 data showed impressive efficacy of T-DXd, with 76% of patients still on therapy at 12 months vs 34% with T-DM1

Clinical Significance:

The treatment landscape for HER2+ mBC is rapidly evolving, with emerging data supporting differentiated approaches for HR+ vs HR– disease and promising results for novel combination strategies that may further improve outcomes.